Wechselwirkungen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 79
HOS-109612 · Präparat HOS-093201
Other benzodiazepines Although not studied, voriconazole (including but not limited to: is likely to increase the plasma triazolam, alprazolam) concentrations of other benzodiazepines that are metabolised by CYP3A4 and lead to a prolonged sedative effect. Cardiovascular agents Ivabradine Although not studied, increased Contraindicated (see section [CYP3A4 substrates] plasma concentrations of 4.3) ivabradine can lead to QTc prolongation and rare occurrences of torsades de pointes. Mavacamten Although not studied, voriconazole Refer to the mavacamten [CYP2C19, CYP3A4 and is likely to increase the plasma summary of product CYP2C9 substrate] concentrations of mavacamten with characteristics (SmPC) for more increased risk of heart failure. information. Cystic fibrosis transmembrane conductance regulator potentiators Ivacaftor Although not studied, voriconazole Dose reduction of ivacaftor is [CYP3A4 substrate] is likely to increase the plasma recommended. concentrations of ivacaftor with risk of increased adverse reactions. Ergot derivatives Ergot alkaloids (including but Although not studied, voriconazole Contraindicated (see section not limited to: ergotamine and is likely to increase the plasma 4.3) dihydroergotamine) concentrations of ergot alkaloids [CYP3A4 substrates] and lead to ergotism. GI motility agents Cisapride Although not studied, increased Contraindicated (see section [CYP3A4 substrate] plasma concentrations of cisapride 4.3) can lead to QTc prolongation and rare occurrences of torsades de pointes. Herbal medicines St. John’s Wort In an independent published study, Contraindicated (see section [CYP450 inducer; Voriconazole AUC0- 59% 4.3) P-gp inducer] 300 mg TID (coadministered with voriconazole 400 mg single dose)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) alprazolam (HOS-086171) mavacamten (HOS-109474) ergot alkaloids (HOS-108807) lead (HOS-085592) ivacaftor (HOS-109475) ivabradine (HOS-109426) ergotamine (HOS-086154) triazolam (HOS-086168) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 13738601987c7c15c8b764a4e09817857affdc23295d0c554fe878df6b4cef0a · Zeichen 20545–22944 im Abschnitt